|
KMID : 1161920150120020039
|
|
Journal of Medicine and Life Science
2015 Volume.12 No. 2 p.39 ~ p.43
|
|
|
Intravenous immunoglobulins in neurological diseases
|
|
Kang Sa-Yoon
|
|
|
Abstract
|
|
|
|
Intravenous immunoglobulin (IVIg) has been used for nearly three decades, and is proving to be an efficient anti-inflammatory and immunomodulatory treatment for a number of neurological diseases. Evidence from randomized controlled clinical trials has established IVIg as a first-line therapy for chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, and multifocal motor neuropathy and the efficacy and safety of IVIg treatment have been summarized in Cochrane systemic reviews. Reports about successful IVIg treatment in other neurological condition exist, but its use remains investigational. IVIg is an effective rescue therapy in exacerbations of myasthenia gravis and is beneficial as a second-line therapy for dermatomyositis and stiff-person syndrome. IVIg has been tested in some neurodegenerative diseases, but a controlled study in Alzheimer disease yielded disappointing results. Despite its widespread use and therapeutic success, the mechanisms of action of IVIg are poorly understood. In addition, questions remain regarding the dose, timing and duration of IVIg treatment in neurological diseases. This review highlights emerging data on the mechanisms of action of IVIg and practical guidelines on administration of IVIg in diverse neurological diseases.
|
|
|
KEYWORD
|
|
|
Evidence, Inflammatory, Intravenous immunoglobulin, Neurological disease, Treatment
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|